Event Abstract

Back to Event

Enabling symptom self-management via use of an electronic patient-reported outcomes (ePRO) system to increase self-efficacy of patients with cancer receiving active chemotherapy treatment

Grigorios Kotronoulas1*, Roma Maguire1, Constantina Papadopoulou1, Eileen Furlong2, Patricia Fox2, Emma Ream1, Jo Armes3, Lisa McCann1, Christine Miaskowski4, Elisabeth Patiraki5, Kathi Apostolidis6 and Nora Kearney1
  • 1 University of Surrey, School of Health Sciences, United Kingdom
  • 2 University College Dublin, Ireland
  • 3 King’s College London, United Kingdom
  • 4 University of California San Francisco, United States
  • 5 National and Kapodistrian University of Athens, Greece
  • 6 European Cancer Patient Coalition, Belgium

Background: In recent years, the shift in cancer services from traditional tertiary care to care delivered within communities has increased the need for patients to engage in self-care activities in order to prevent or reduce the severity of numerous and complex-side effects (McCorkle et al., 2011) and make important health decisions when at home in the absence of clinicians (Butow et al., 2012). The actual degree of engagement in self-management may be dependent on patients’ perceived competence or self-efficacy to perform such activities (Fenlon et al., 2015). Self-efficacy has been defined as “a person’s belief to execute courses of action required to deal with a prospective situation” (Bandura, 1977, 2001). One’s beliefs in their capability to successfully manage tasks and consequently influence situations that impact their lives constitutes a central part of human agency, and can be influenced by performance accomplishments (Bandura, 1989, 2001). Whilst self-efficacy can enable engagement in self-management, actual participation in self-management activities can further increase one’s perceived ability to undertake such activities; it is thus obvious that a bi-directional association between self-management and self-efficacy exists. Supporting a shift in clinical practice with innovative technological systems affords a solution to the increasing demands placed on acute care by enabling the delivery of care in the home and community setting (Basch et al., 2011; Carpenter et al., 2008). Such remote monitoring systems facilitate the provision of clear lines of real-time communication between patients and their health care providers (Basch et al., 2011), and can deliver organised self-management advice tailored to the individual’s clinical characteristics and severity/distress of symptoms of anti-cancer treatment. Aim(s): Funded by the European Union (FP7 programme), a multi-centre European project (the eSMART study) has been designed to investigate the effects of an electronic patient-reported outcomes (ePRO) system, the Advanced Symptom Management System (ASyMS), on patient outcomes including improvement in self-efficacy, symptom management, supportive care needs, psychological status, work presenteeism, and well-being; health system costs; and the current clinical practice. The primary aim of eSMART is to evaluate the short and long term impact of the ASyMS technology on patient reported outcomes in people with breast cancer, colorectal cancer or haematological malignancies receiving first-line chemotherapy. In addition, eSMART will evaluate the cost-benefit of remote patient-monitoring and changes in clinical practice as a result of the application of the ASyMS intervention in different European healthcare settings. The study is currently recruiting patients, thus no data will be available for presentation. This presentation will nonetheless aim to present and discuss the hypothesis that provision of symptom self-management advice may be an important mechanism to improve patient self-efficacy, which may establish a self-sustained cycle where self-care advice provision enables patient self-efficacy and this in turn further increases patient involvement in self-management that can ultimately lead to improved patient outcomes. Method(s)/Results: The current study has been informed by the Medical Research Council Complex Interventions Framework (Anderson, 2008; Craig and Petticrew, 2012; Mackenzie et al., 2010), and the Holistic Framework to improve the Uptake and Impact of e-Health Technologies (van Gemert-Pijnen et al., 2011). The eSMART programme of work comprises two parts that will take place over a period of five years. The first part consists of preparatory work to refine the ASyMS intervention for use in a multi-national context, and concludes with a feasibility testing period to establish the technological readiness of the system prior to its use in the second part. The second part will employ a repeated-measures, parallel-group, stratified randomised controlled trial methodology to demonstrate the effects of the ASyMS intervention in supporting patients who receive chemotherapy treatment through individualised symptom management. The second part will test the short- (i.e. during the treatment phase) and long-term effects (i.e. at one-year follow-up) of the ASyMS intervention versus standard care across the participating countries (Austria, Greece, Ireland, Norway and the UK). The ASyMS intervention comprises use of a mobile phone (i.e. ASyMS patient handset) and a tympanic thermometer. The patient handset will enable participants on the intervention group to enter symptom/temperature data on a dedicated, electronic symptom questionnaire daily and whenever they feel unwell. Upon successful submission of their data, patients will immediately receive automated, evidence-based self-care advice based on their symptom reports. Patients will also have access to a self-care library, symptom graphs (detailing trends in individual symptoms experienced) and contact numbers of care teams and patient support organisations in their country, available within the ASyMS patient handset. Via dedicated tablet PCs, all participants will complete an electronic version of the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-Cancer) (Wolf et al., 2005) at baseline; after each CTx; and 3, 6, 9 and 12 months post-chemotherapy treatment. The CASE-Cancer is a validated, 12-item measure that yields scores on three factors: understanding and participating in care, maintaining a positive attitude, and seeking and obtaining information. In accordance with latest recommendations for pragmatic research in healthcare (Oakley et al., 2006; Treweek and Zwarenstein, 2009), the longitudinal nature of the trial will aid to establish sustainability of intervention effects and further stress its benefits when compared to standard care. Conclusions: This anticipatory model of care supports symptom management within the patient’s home, where the early toxicities of chemotherapy can be managed, utilising self-care and local community services. This model is also expected to contribute to the health literacy of patients with cancer in relation to early identification, report and self-management of their most common symptoms. As part of the project’s objectives, we will aim to show improved self-efficacy (as shown by statistically significantly higher self-efficacy scores) during active chemotherapy for breast cancer, colorectal cancer, or haematological malignancies, and/or at one-year follow-up. It is hoped that an enhanced self-efficacy (evidenced by patients’ greater understanding and participation in care, positive attitude, and engagement in seeking health-related information) will in turn enable a smoother rehabilitation process for patients in the post-treatment survivorship period and beyond. EU FP7 Programme Grant agreement No. 602289. Trial registration identifier (clinicaltrials.gov) NCT02356081.

Acknowledgements

The authors gratefully acknowledge the contribution of the eSMART Collaborative Work Group in this project.

References

Anderson, R., 2008. New MRC guidance on evaluating complex interventions. BMJ 337, a1937.
Bandura, A., 1977. Self-efficacy: Toward a Unifying Theory of Behavioral Change. Psychological review 84, 191-215.
Bandura, A., 1989. Human agency in social cognitive theory. Am Psychol 44, 1175-1184.
Bandura, A., 2001. Social cognitive theory: an agentic perspective. Annu Rev Psychol 52, 1-26.
Basch, E.M., Reeve, B.B., Mitchell, S.A., Clauser, S.B., Minasian, L., Sit, L., et al., 2011. Electronic toxicity monitoring and patient-reported outcomes. Cancer J 17, 231-234.
Butow, P.N., Phillips, F., Schweder, J., White, K., Underhill, C., Goldstein, D., 2012. Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer 20, 1-22.
Carpenter, J.S., Rawl, S., Porter, J., Schmidt, K., Tornatta, J., Ojewole, F., et al., 2008. Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum 35, 661-669.
Craig, P., Petticrew, M., 2012. Developing and evaluating complex interventions: Reflections on the 2008 MRC guidance. Int J Nurs Stud.
Fenlon, D.R., Khambhaita, P., Hunter, M.S., 2015. Helping Patients to Help Themselves after Breast Cancer Treatment. Clin Oncol (R Coll Radiol).
Mackenzie, M., O'Donnell, C., Halliday, E., Sridharan, S., Platt, S., 2010. Do health improvement programmes fit with MRC guidance on evaluating complex interventions? BMJ 340, c185.
McCorkle, R., Ercolano, E., Lazenby, M., Schulman-Green, D., Schilling, L.S., Lorig, K., et al., 2011. Self-management: Enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin 61, 50-62.
Oakley, A., Strange, V., Bonell, C., Allen, E., Stephenson, J., 2006. Process evaluation in randomised controlled trials of complex interventions. BMJ 332, 413-416.
Treweek, S., Zwarenstein, M., 2009. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 10, 37.
van Gemert-Pijnen, J.E., Nijland, N., van Limburg, M., Ossebaard, H.C., Kelders, S.M., Eysenbach, G., et al., 2011. A holistic framework to improve the uptake and impact of eHealth technologies. Journal of medical Internet research 13, e111.
Wolf, M.S., Chang, C.H., Davis, T., Makoul, G., 2005. Development and validation of the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer). Patient Educ Couns 57, 333-341.

Keywords: Cancer, Technology, self-management, self-efficacy, ePRO system, patient-reported outcomes, chemotherapy, randomized controlled trial, empowerment

Conference: 2nd Behaviour Change Conference: Digital Health and Wellbeing, London, United Kingdom, 24 Feb - 25 Feb, 2016.

Presentation Type: Oral presentation

Topic: Academic

Citation: Kotronoulas G, Maguire R, Papadopoulou C, Furlong E, Fox P, Ream E, Armes J, McCann L, Miaskowski C, Patiraki E, Apostolidis K and Kearney N (2016). Enabling symptom self-management via use of an electronic patient-reported outcomes (ePRO) system to increase self-efficacy of patients with cancer receiving active chemotherapy treatment. Front. Public Health. Conference Abstract: 2nd Behaviour Change Conference: Digital Health and Wellbeing. doi: 10.3389/conf.FPUBH.2016.01.00077

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 27 Nov 2015; Published Online: 09 Jan 2016.

* Correspondence: Dr. Grigorios Kotronoulas, University of Surrey, School of Health Sciences, Guildford, United Kingdom, grigorios.kotronoulas@strath.ac.uk